Androgenic Effects on Ventricular Repolarization A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes
- 23 September 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 140 (13), 1070-1080
- https://doi.org/10.1161/CIRCULATIONAHA.119.040162
Abstract
Background: Male hypogonadism, arising from a range of etiologies including androgen-deprivation therapies (ADTs), has been reported as a risk factor for acquired long-QT syndrome (aLQTS) and torsades de pointes (TdP). A full description of the clinical features of aLQTS associated with ADT and of underlying mechanisms is lacking. Methods: We searched the international pharmacovigilance database VigiBase for men (n=6 560 565 individual case safety reports) presenting with aLQTS, TdP, or sudden death associated with ADT. In cardiomyocytes derived from induced pluripotent stem cells from men, we studied electrophysiological effects of ADT and dihydrotestosterone. Results: Among subjects receiving ADT in VigiBase, we identified 184 cases of aLQTS (n=168) and/or TdP (n=68; 11% fatal), and 99 with sudden death. Of the 10 ADT drugs examined, 7 had a disproportional association (reporting odds ratio=1.4-4.7; P<0.05) with aLQTS, TdP, or sudden death. The minimum and median times to sudden death were 0.25 and 92 days, respectively. The androgen receptor antagonist enzalutamide was associated with more deaths (5430/31 896 [17%]; P<0.0001) than other ADT used for prostate cancer (4208/52 089 [8.1%]). In induced pluripotent stem cells, acute and chronic enzalutamide (25 mu M) significantly prolonged action potential durations (action potential duration at 90% when paced at 0.5 Hz; 429.7 +/- 27.1 (control) versus 982.4 +/- 33.2 (acute, P<0.001) and 1062.3 +/- 28.9 ms (chronic; P<0.001), and generated afterdepolarizations and/or triggered activity in drug-treated cells (11/20 acutely and 8/15 chronically). Enzalutamide acutely and chronically inhibited delayed rectifier potassium current, and chronically enhanced late sodium current. Dihydrotestosterone (30 nM) reversed enzalutamide electrophysiological effects on induced pluripotent stem cells. Conclusions: QT prolongation and TdP are a risk in men receiving enzalutamide and other ADTs.Keywords
This publication has 36 references indexed in Scilit:
- Outlier removal to uncover patterns in adverse drug reaction surveillance – a simple unmasking strategyPharmacoepidemiology and Drug Safety, 2013
- Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT SyndromeScience Translational Medicine, 2012
- Testosterone and Vascular Function in AgingFrontiers in Physiology, 2012
- Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular RiskCirculation, 2010
- Effects of Testosterone on Ventricular Repolarization in Hypogonadic MenThe American Journal of Cardiology, 2009
- Anti-HERG activity and the risk of drug-induced arrhythmias and sudden deathEuropean Heart Journal, 2005
- Drug-Induced Prolongation of the QT IntervalThe New England Journal of Medicine, 2004
- Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndromeJournal of the American College of Cardiology, 1994
- FinasterideThe New England Journal of Medicine, 1994
- Female Gender as a Risk Factor for Torsades de Pointes Associated With Cardiovascular DrugsPublished by American Medical Association (AMA) ,1993